Trash_Panda-1 t1_j6931xz wrote on January 28, 2023 at 5:02 PM

Reply to comment by Trash_Panda-1 in Abbvie to lose most lucrative patent protection one week before Q4 earnings call. by [deleted]

https://preview.redd.it/03rw99qzwuea1.png?width=557&format=pjpg&auto=webp&v=enabled&s=392c379b92150accf7352b0872b68ca0028e68a4

Abbvie has had the Humira patent since 2002 I believe, (remember 43% of sales last year) does this chart really show an adequate correction for losing a monopoly on 43% of sales?

Taiyonay t1_j69sk23 wrote on January 28, 2023 at 7:55 PM

They don't lose their patent for certain indications and this was known for years that it was coming as they have been in and out of court for a while trying to defend the patent. Only one biosimilar hits the market now. More can be released in July. Probably won't see any major change until start of quarter 3

Edit to also add that they have had recent success with expanded indication approvals for skyrizi and rinvoq to replace humira in the market share and they are actually doing really well with prescribers. Abbvie has some top notch drug reps and a really great bridge to coverage programs that have expanded access to these other drugs drastically.